AiBIOLOGICS

AiBIOLOGICS: Advancing antibody, diagnostics, and vaccine discovery through the power of artificial intelligence. AiBIOLOGICS is a biotechnology company founded in 2019 and headquartered in Ireland. The company specializes in utilizing AI and deep learning algorithms, particularly its EpitopePredikt software, to aid in antibody discovery, diagnostic research, immunoassay development, and vaccine development. The EpitopePredikt software is instrumental in identifying immunodominant sequences within any protein from any species and determining the most likely antibody class or subtype to respond to the epitope. AiBIOLOGICS also offers novel immunoassay raw materials, antigens, immunogens, antibodies, and vaccine subunits, presenting groundbreaking advancements to its customers in the biotechnology industry. With expertise in antibody discovery, diagnostic research, immunoassay development, and vaccine development, AiBIOLOGICS aims to assist and advance projects in these fields through its innovative technology. As of now, there is no public record of the last investment or the investors involved in AiBIOLOGICS.